OraSure Technologies, Inc. (NASDAQ:OSUR)

FDA approval of an over-the counter HIV test, which gives results in 20 minutes in the privacy of your own home, would give OSUR a leading edge in $3.5 billion global HIV/Aids testing market.

OraSure stock has been on an upswing since receiving notification of receipt of a CLIA waiver allowing them to market their OraQuick HCV test to outpatient clinics and physician offices. I see the greatest usefulness of the quick HCV test as a rapid screen to weed out unusable blood product donors. HCV might be an important condition to screen for in those other outpatient settings, but why does the result of that test need to come back right away while other equally important tests go to the lab? It's not like you're going to get a prescription for Incivek as you walk out the door. Even if the CLIA waiver ends up increasing test revenues, the effect likely won't be seen for several quarters as the company continues to burn cash and reserves get lower. The same goes for the OraQuick OTC HIV test, which has just completed clinical testing but won't be acted on by the FDA for months. Quarterly burn has been 2-4M and cash reserves were 21M as of the last PR.

WOW! Now this stock is overvalued!

When you subtract stock based compensation from free cash flow you begin to see just how unprofitable this company is. Only those who don't know what they are doing would invest in this terrible company.

money loser...

growing industry

trendspotter

Quick test result product for Hep. C due in 2011. Testing is where it is at for the future.

Looks like this company is finally on track to get approvals for both of its best prospective tests which will save or lengthen lives.

nicht ein wiederkauf

Five star stock bouncing off of a recent low.

More than CMS, it's Premier's endorsement/contract that made me bullish on this long-term watchlist candidate.

Management has underperformed in nearly every aspect in the past 4 years. Sales have fallen as products underperformed and continued delays in FDA approval of OTC oraquick product.

The fiest quarter of 2009 should prove the low point in company sales and earnings. Cryo produces are once again being dstributed (all be it in a limited form) after a year without distribution. FDA approval of HEP C should take place later this year and the light at the end of the (FDA OTC) approval for oraquick.

The market will discount these new revenue streams within the next few months (normally 6-9 months prior to FDA approval.

The company has nearly 1.62 / share net working capital and only trades about $1.00 above that level.

This is my first rating on CAPS so take everything with a grain of salt.

good luck

Do your own research

Hiv testing should be given priority

Beaten down recently on concerns over its HIV test and legal issues, but still has excellent prospects for its over-the-counter oral fluid HIV test and its hepatitis C test for healthcare professionals.

From my short ideas/valuation screen

HIV test in 20 minutes is amazing in this day and age where faster and easier is better

Hometown company, but yea they have the hiv oral testing which is good, but cant wait for their products in the pipeline.

No blood or urine needed. Aids amd drug testing made simple and cheap. This is a definite take over down the road.

Fool ratio is 15.9. Well, at least they are profitable. Do they have any new products in the pipeline?